BioPharma Resources

Drugs by condition

Drugs approved for dry eye disease

Brand-name prescription drugs and biologics whose FDA label lists dry eye disease as an approved use. Matched on the label phrases: "dry eye".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

7

Still marketed, NDA or BLA

Drug classes

5

Novel drugs

4

New molecular entities and new biologics

In development

13

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for dry eye disease.

  • Tryptyr (Acoltremon) · Alcon Labs INC NovelMay 28, 2025
  • Vevye (Cyclosporine) · Harrow Eye May 30, 2023
  • Miebo (Perfluorohexyloctane) · Bausch and Lomb INC NovelMay 18, 2023
  • Tyrvaya (Varenicline Tartrate) · Harrow Eye Oct 15, 2021
  • Eysuvis (Loteprednol Etabonate) · Alcon Labs INC NovelOct 26, 2020

All approved drugs for dry eye disease, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 1 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Calcineurin Inhibitor Immunosuppressant (2)

  • Vevye Cyclosporine · Harrow Eye · 2023
  • Cequa Cyclosporine · Sun Pharm · 2018

TRPM8 Thermoreceptor Agonist (1)

  • Tryptyr Acoltremon · Alcon Labs INC · 2025

Semifluorinated Alkane (1)

  • Miebo Perfluorohexyloctane · Bausch and Lomb INC · 2023

Lymphocyte Function-Associated Antigen-1 Antagonist (1)

  • Xiidra Lifitegrast · Bausch and Lomb INC · 2016

Class not listed in FDA's data (2)

  • Eysuvis Loteprednol Etabonate · Alcon Labs INC · 2020
  • Tyrvaya Varenicline Tartrate · Harrow Eye · 2021

Drugs in development for dry eye disease

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • DFL24498Phase 32 trials

    Dompé Farmaceutici S.p.A · Dry Eye Disease (DED), Atopic Keratoconjunctivitis

  • ABBV-444Phase 31 trial

    AbbVie · Dry Eye Disease

  • CAM-101Elate Ocular, FD hPLPhase 31 trial

    Cambium Bio Limited · Dry Eye Disease, Dry Eye, Dry Eyes Chronic

  • licaminlimabPhase 31 trial

    Oculis · Dry Eye Disease (DED)

  • SJP-0132Phase 31 trial

    Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. · Dry Eye

  • VVN001Phase 31 trial

    VivaVision Biotech, Inc · Dry Eye

  • 0.25% RCI001RCI001Phase 22 trials

    ORA, Inc. · Dry Eye Disease (DED), Dry Eye

  • BL1107Phase 22 trials

    Bausch & Lomb Incorporated · Dry Eye Disease, Glaucoma

  • TTAX03Phase 22 trials

    BioTissue Holdings, Inc · Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis

  • BRM421Phase 21 trial

    BRIM Biotechnology Inc. · Dry Eye Disease (DED), Keratoconjunctivitis Sicca

  • BTV100Phase 21 trial

    BioTheraVision, Inc. · Dry Eye

  • TJO-087Phase 21 trial

    Taejoon Pharmaceutical Co., Ltd. · Dry Eye Syndrome (DES)

  • VSJ-110Phase 21 trial

    Vanda Pharmaceuticals · Dry Eye

More on dry eye disease: recruiting trials · published research

Related in ophthalmology: Wet macular degeneration · Diabetic macular edema · Glaucoma · Geographic atrophy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.